CLINICAL TRIAL ONPALSINURON CAPSULE FOR TREATMENT OF DIABETIC NEUROPATHY
Phase 4
Not yet recruiting
- Conditions
- Health Condition 1: null- Patients of Type II Diabetes Mellitus diagnosed with diabetic peripheral sensorimotor neuropathy
- Registration Number
- CTRI/2017/07/009087
- Lead Sponsor
- Ms SG Phyto Pharma Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Metabolically stable diabetic patients with symptomatic diabetic sensorimotor polyneuropathy (DSPN)
2.Patients of either sex between the age group of 35-65 years.
3. HbA1c not exceeding 11
Exclusion Criteria
1.Patients who are insulin dependent.
2.Patients with other metabolic and endocrinal disorders.
3.Patients with other causes of Polyneuropathy.
4.Patients suffering from infectious diseases.
5.Patients with non healing ulcer/ulcers.
6.Patients with Diabetic Polyneuropathy in stage N3 of Dyckâ??s staging
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Palsinuron's efficacy in treating diabetic peripheral sensorimotor neuropathy?
How does Palsinuron compare to standard-of-care treatments like alpha-lipoic acid in managing type II diabetes-related neuropathy?
Are there specific biomarkers that can predict patient response to Palsinuron therapy in diabetic neuropathy?
What are the potential adverse events associated with Palsinuron and how are they managed in clinical practice?
What related compounds or combination therapies are being explored by SG Phyto Pharma for diabetic neuropathy alongside Palsinuron?